Back

Hospital length of stay for severe COVID-19: implications for Remdesivir's value

2020-08-12 health policy Title + abstract only
View on medRxiv
Show abstract

Remdesivir has been granted emergency use authorization for treatment of severe COVID-19. Remdesivir's pricing is based on a presumed reduction of hospital length of stay (LOS) by four days. But the Adaptive COVID-19 Treatment Trial (ACTT-1) that suggested this treatment benefit excluded patients who were expected to be discharged within 72 hours. Perhaps as a result, median time to recovery was unusually long in both arms of the study (15 days vs 11 days). Remdesivir requires a 5-day inpatient ...

Predicted journal destinations

1
PLOS ONE
1737 training papers
Top 9% 36.5%
2
JAMA Network Open
125 training papers
#1 17.2%
3
BMJ Open
553 training papers
Top 20% 7.5%
4
Scientific Reports
701 training papers
Top 36% 6.6%
5
Open Forum Infectious Diseases
124 training papers
Top 2% 4.5%
6
Clinical Infectious Diseases
219 training papers
Top 13% 2.3%
7
Annals of Internal Medicine
27 training papers
#1 1.8%
8
International Journal of Infectious Diseases
115 training papers
Top 10% 1.8%
9
Vaccines
131 training papers
Top 6% 1.6%
10
BMC Public Health
148 training papers
Top 22% 1.4%
11
Proceedings of the National Academy of Sciences
100 training papers
Top 14% 1.1%
12
PLOS Medicine
95 training papers
Top 14% 1.1%
13
Journal of Medical Internet Research
81 training papers
Top 18% 0.8%
14
Journal of Clinical Investigation
50 training papers
Top 5% 0.8%
15
Med
26 training papers
Top 1% 0.6%
16
mBio
34 training papers
Top 4% 0.6%
17
Frontiers in Public Health
135 training papers
Top 38% 0.5%
18
Clinical Microbiology and Infection
54 training papers
Top 11% 0.5%
19
JMIR Public Health and Surveillance
45 training papers
Top 13% 0.5%
20
Vaccine
140 training papers
Top 13% 0.5%
21
eClinicalMedicine
55 training papers
Top 8% 0.5%
22
Nature Medicine
88 training papers
Top 24% 0.5%
23
International Journal of Environmental Research and Public Health
116 training papers
Top 38% 0.5%